Andrew Dudum Sells 188,888 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares of the company’s stock, valued at approximately $1,399,273.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Andrew Dudum also recently made the following trade(s):

• On Friday, September 20th, Andrew Dudum sold 45,767 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.33, for a total value of $747,375.11.
• On Tuesday, September 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28.

Hims & Hers Health Stock Down 0.9 %

HIMS stock opened at $23.41 on Friday. The business’s 50-day moving average price is $18.75 and its 200-day moving average price is $18.45. The stock has a market cap of $5.03 billion, a P/E ratio of 53.21 and a beta of 1.06. Hims & Hers Health, Inc. has a twelve month low of $6.58 and a twelve month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Intech Investment Management LLC bought a new stake in Hims & Hers Health during the third quarter valued at about $1,064,000. Quest Partners LLC boosted its stake in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the period. Royce & Associates LP grew its position in shares of Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Victory Capital Management Inc. raised its stake in Hims & Hers Health by 164.9% during the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after purchasing an additional 32,108 shares during the period. Finally, WealthPlan Investment Management LLC purchased a new position in Hims & Hers Health in the 3rd quarter worth approximately $1,042,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Truist Financial raised their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.21.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.